- Home
- ALNY vs ROP Comparison
ALNY vs ROP Comparison
Compare ALNY & ROP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- ROP
- Stock Information
- Founded
- ALNY 2002
- ROP 1981
- Country
- ALNY United States
- ROP United States
- Employees
- ALNY N/A
- ROP N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- ROP Industrial Machinery/Components
- Sector
- ALNY Health Care
- ROP Industrials
- Exchange
- ALNY Nasdaq
- ROP Nasdaq
- Market Cap
- ALNY 60.7B
- ROP 58.3B
- IPO Year
- ALNY 2004
- ROP 1992
- Fundamental
- Price
- ALNY $452.03
- ROP $450.32
- Analyst Decision
- ALNY Strong Buy
- ROP Buy
- Analyst Count
- ALNY 27
- ROP 13
- Target Price
- ALNY $483.89
- ROP $602.83
- AVG Volume (30 Days)
- ALNY 1.1M
- ROP 1.1M
- Earning Date
- ALNY 10-30-2025
- ROP 10-23-2025
- Dividend Yield
- ALNY N/A
- ROP 0.74%
- EPS Growth
- ALNY N/A
- ROP 6.17
- EPS
- ALNY 0.33
- ROP 14.52
- Revenue
- ALNY $3,210,070,000.00
- ROP $7,721,000,000.00
- Revenue This Year
- ALNY $65.55
- ROP $13.76
- Revenue Next Year
- ALNY $41.48
- ROP $8.59
- P/E Ratio
- ALNY $1,376.27
- ROP $30.84
- Revenue Growth
- ALNY 53.24
- ROP 13.95
- 52 Week Low
- ALNY $205.87
- ROP $435.42
- 52 Week High
- ALNY $495.55
- ROP $595.17
- Technical
- Relative Strength Index (RSI)
- ALNY 50.48
- ROP 36.15
- Support Level
- ALNY $417.00
- ROP $441.03
- Resistance Level
- ALNY $459.27
- ROP $455.80
- Average True Range (ATR)
- ALNY 16.59
- ROP 9.73
- MACD
- ALNY -0.57
- ROP 0.80
- Stochastic Oscillator
- ALNY 54.18
- ROP 30.65
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About ROP Roper Technologies Inc.
Roper Technologies is a holding company focused on acquiring, managing, and developing niche market-leading technology businesses. The company operates a decentralized business model whereby each portfolio company operates independently from the others. Roper positions itself as a free cash flow compounder, whereby excess free cash flow generated by its portfolio businesses is repatriated to the parent company, which is then utilized to acquire additional businesses. Presently, the company operates 30 distinct businesses with over three-fourths of the revenue coming from software products and over two-thirds of revenue coming from recurring and reoccurring sources.